New Research Suggests Bempedoic Acid Outperforms Ezetimibe for Heart Health in Patients with Type 2 Diabetes

New clinical data released at the American Diabetes Association’s 2026 Scientific Sessions reveals a potentially game-changing shift in how health care providers manage cardiovascular risk in patients with type 2 diabetes. While ezetimibe (Zetia; Organon & Co) has long served as the conventional first-line non-statin therapy, a massive real-world study suggests that bempedoic acid (Nexletol; Esperion) may offer superior protection against major cardiovascular events, even when it results in a smaller absolute reduction of cholesterol levels.¹

A Unique Mechanism of Action

Bempedoic acid is a relatively new lipid-lowering agent, having received FDA approval in February 2020. It acts as a first-in-class adenosine triphosphate-citrate-lyase (ACL) inhibitor. By inhibiting ACL, the drug restricts the substrate pool needed for cholesterol and fatty acid synthesis, effectively upregulating low-density lipoprotein (LDL) receptors and enhancing the clearance of "bad" cholesterol from the blood.²

One of the drug's most significant advantages over traditional statins is its liver-specific nature. Administered as a prodrug, bempedoic acid is activated by an enzyme (ACSVL1) that is present in the liver but absent in skeletal muscle. This unique pharmacokinetic profile helps minimize the muscle-related adverse effects, such as myalgia and spasms, that frequently cause patients to discontinue statin therapy.²

The Comparative Study

The new research, a retrospective cohort study using the TriNetX real-world database, analyzed data from over 130 million patients across 112 health care organizations. Researchers focused on adults with type 2 diabetes who were already on moderate-intensity statin therapy but required additional LDL-C lowering. The study compared nearly 3000 propensity-matched patients who were prescribed either bempedoic acid or ezetimibe as an add-on treatment.

The findings were striking: bempedoic acid was associated with a 35% lower risk of a composite cardiovascular endpoint, which included stroke, myocardial infarction (heart attack), and new-onset heart failure. Individual end points in the study all favored bempedoic acid over ezetimibe.¹

The LDL Paradox

The most surprising aspect of the data was that ezetimibe actually achieved a greater mean reduction in LDL-C from baseline (-30.9 mg/dL) compared to bempedoic acid (-21 mg/dL). Despite the smaller drop in cholesterol, the bempedoic acid cohort experienced significantly better clinical outcomes. This suggests that the cardiovascular benefits of bempedoic acid in diabetic populations may involve mechanisms beyond simple lipid reduction.

Clinical Considerations

Current medical guidelines, including the American Diabetes Association’s 2024 standards, already endorse bempedoic acid for diabetic patients who cannot tolerate statins. However, these new data could broaden its use for those who are currently taking statins but remain at high residual risk.

While generally well-tolerated, bempedoic acid is not without risks. Clinicians must monitor patients for hyperuricemia and gout, which occurred in approximately 1% of patients in clinical trials, as well as the rare but serious risk of tendon rupture.^1,2

As cardiovascular disease remains a leading cause of death for those with type 2 diabetes, these findings provide a compelling case for re-evaluating standard add-on therapies. For many, the choice of a liver-specific ACL inhibitor may soon become the preferred path for long-term heart protection.

REFERENCES

1. Ansong B, White R, Cowart K. Association of cardiovascular outcomes with bempedoic acid vs ezetimibe added to moderate-intensity statin therapy in people with type 2 diabetes. Presented at: American Diabetes Association 2026 Scientific Sessions. June 5-8, 2026. New Orleans, LA.

2. Chandramahanti S, Patel P, Farzam K. Bempedoic Acid. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2026 Jan.